Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.
2.
3.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
4.

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Uhry S, Bessereau J, Camoin-Jau L, Paganelli F, Bonello L.

Hosp Pract (1995). 2012 Apr;40(2):104-17. doi: 10.3810/hp.2012.04.976. Review.

PMID:
22615085
5.

Response variability to P2Y12 receptor inhibitors: expectations and reality.

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy)..

JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. doi: 10.1016/j.jcin.2013.06.011. Review.

6.

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY.

Lancet. 2012 May 5;379(9827):1705-11. doi: 10.1016/S0140-6736(12)60161-5.

PMID:
22464343
7.

The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.

Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, Angiolillo DJ, Nolin TD, Maa JF, Bailey WL, Jakubowski JA, Ojeh CK, Jeong YH, Tantry US, Baker BA.

J Am Coll Cardiol. 2013 Aug 6;62(6):505-12. doi: 10.1016/j.jacc.2013.03.037.

8.

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA.

Circ Cardiovasc Genet. 2010 Dec;3(6):556-66. doi: 10.1161/CIRCGENETICS.110.958561.

9.

Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.

Smock KJ, Saunders PJ, Rodgers GM, Johari V.

Am J Hematol. 2011 Dec;86(12):1032-4. doi: 10.1002/ajh.22112. Review.

10.

The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.

Namazi S, Kojuri J, Khalili A, Azarpira N.

Biochem Pharmacol. 2012 Apr 1;83(7):903-8. doi: 10.1016/j.bcp.2012.01.003.

PMID:
22265638
11.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
12.

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F.

Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463.

13.

Clinical use of clopidogrel.

Sarafoff N, Byrne RA, Sibbing D.

Curr Pharm Des. 2012;18(33):5224-39. Review.

PMID:
22724411
14.

Recent advances in the pharmacogenetics of clopidogrel.

Cuisset T, Morange PE, Alessi MC.

Hum Genet. 2012 May;131(5):653-64. doi: 10.1007/s00439-011-1130-6. Review.

PMID:
22207144
15.

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.

Gurbel PA, Bliden KP, Antonino MJ, Stephens G, Gretler DD, Jurek MM, Pakyz RE, Shuldiner AR, Conley PB, Tantry US.

J Thromb Haemost. 2010 Jan;8(1):43-53. doi: 10.1111/j.1538-7836.2009.03648.x.

16.

Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.

Sibbing D, Bernlochner I, Kastrati A, Paré G, Eikelboom JW.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):505-13; discussion 513. doi: 10.1161/CIRCINTERVENTIONS.111.962183. Review. No abstract available.

17.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators..

Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378.

PMID:
23223867
18.
19.

Bedside evaluation of thienopyridine antiplatelet therapy.

Price MJ.

Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732. Review. No abstract available.

20.
Items per page

Supplemental Content

Support Center